MAJI (Exousia Pro) Total Stockholders Equity: $-0.45 Mil (As of Jan. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Exousia Pro Total Stockholders Equity?

Exousia Pro MAJI Total Stockholders Equity is $-0.45 Mil as of Jan. 2021.

Exousia Pro's Total Stockholders Equity for the quarter that ended in Jan. 2021 was $-0.45 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Exousia Pro's Book Value per Share for the quarter that ended in Jan. 2021 was $-0.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Exousia Pro's Debt-to-Equity for the quarter that ended in Jan. 2021 was -0.56.

Exousia Pro  (OTCPK:MAJI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Exousia Pro's Book Value per Share for the quarter that ended in Jan. 2021 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-0.445-0)/12.492
=-0.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Exousia Pro's Debt-to-Equity for the quarter that ended in Jan. 2021 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.247 + 0) / -0.445
=-0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro Total Stockholders Equity Related Terms

Exousia Pro Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Exousia Pro's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro Total Stockholders Equity Chart

Exousia Pro Annual Data
Trend Apr11 Apr12 Apr18 Apr19 Apr20
Total Stockholders Equity
-0.03 -0.27 -0.09 -0.21 -0.39

Exousia Pro Quarterly Data
Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.39 -0.46 -0.43 -0.45
What does a Total Stockholders Equity of $-0.45 Mil mean?
Exousia Pro (MAJI) has a Total Stockholders Equity of $-0.45 Mil as of Jan. 2021. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Exousia Pro and its competitors.
Is Exousia Pro's Total Stockholders Equity too high?
Exousia Pro's current Total Stockholders Equity is $-0.45 Mil.
How does Exousia Pro's Total Stockholders Equity compare to HCCH and GRNV?
Exousia Pro's Total Stockholders Equity of $-0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Exousia Pro and its competitors. Exousia Pro's current Total Stockholders Equity is $-0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current Total Stockholders Equity of $-0.45 Mil. The current Total Stockholders Equity is $-0.45 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Exousia Pro (MAJI), the current Total Stockholders Equity is $-0.45 Mil as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.